Clinical trial
PS-341 in Treating Patients With Metastatic Malignant Melanoma
NCT00024011 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00024011 |
|---|---|
| Title | PS-341 in Treating Patients With Metastatic Malignant Melanoma |
| Official title | A Phase II Study of PS-341 in the Treatment of Metastatic Malignant Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | bortezomib, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Jul 1, 2001 |
| Primary completion | Sep 1, 2006 |
| First posted | Feb 6, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: